U.S. Stock Tracking – June 5, 2020

The company is divided into diagnostic substances and therapeutic development programs; it has developed the Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. The CD206-targeting drug platform is applicable to multiple diagnostic modalities, including single-photon emission computed tomography (SPECT), positron emission tomography (PET), imaging and localized gamma scanning, as well as intraoperative and/or optical fluorescence detection—serving as a delivery system for therapeutic compounds targeting macrophages and immune- and inflammation-related diseases. It offers NAV4694, a fluorine-18–labeled PET imaging agent for imaging and evaluating patients exhibiting signs or symptoms of Alzheimer’s disease and mild cognitive impairment. It develops diagnostic agents, including technetium Tc 99m tilmanocept and other diagnostic applications of its Manocept platform, along with various other therapeutic development programs. The company collaborates with IMV Inc. on preclinical therapeutic research to explore the potential synergistic effects of its platform-based immunotherapies. The company’s total revenue has declined year-on-year; however, it rose quarter-on-quarter in Q1 2020, while losses widened. Cash on hand decreased year-on-year and remains tight; non-current deferred revenue remained stable. Its stock price hit a low of $0.63 on April 16, 2020, and surged 4.45% on June 23. On June 26, the stock opened 2.25% higher, then declined to −4.26%, fluctuated with upward and downward movements, and finally closed down 0.5% above the opening price. Turnover was 1.55%. Market capitalization was slightly higher than enterprise value. A total of 28 institutions held shares, accounting for 7.02% of total shares outstanding. No analyst recommendations were available. Upside momentum carries risk; trading volume is low—caution is advised. LXU (LSB Industries, Inc.) Manufactures and sells chemical products in the United States; founded in 1968, headquartered in Oklahoma City, Oklahoma. The company supplies nitrogen-based fertilizers, such as ammonium hydroxide, fertilizer-grade ammonium nitrate (HDAN), and urea-ammonium nitrate solutions, as well as fertilizer blends for corn and other crops—including NPK fertilizer blends. It also provides high-purity and commercial-grade ammonia, high-purity ammonium nitrate, sulfuric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid; concentrated, mixed, and conventional nitric acid for diverse applications (including semiconductors); polyurethane intermediates; pulp and paper production; alum; water treatment; metal and vanadium processing; power plant emission reduction; refrigerants and metal processing; exhaust additives; horticultural/greenhouse applications; refrigeration; and industrial-grade ammonium nitrate, ammonium nitrate solution, and HDAN solution for specialty emulsions used in mining, open-pit mining, quarrying, and construction. The company’s total revenue declined year-on-year over the past two years. Net income turned deeper into loss in Q1 2020. Cash on hand remains ample. Its stock price peaked at $4.37 on January 17, 2020, and bottomed at $1.04 on May 19. On June 26, the stock opened 0.46% higher, then oscillated downward to −3.67%, experienced multiple ups and downs, rallied late in the session to +5.5%, and closed up 3.67% from the opening price. Turnover reached 8.41%. Market capitalization was far below enterprise value. A total of 135 institutions held shares, representing 84.86% of total shares outstanding. One analyst issued a strong buy recommendation—worth monitoring. PHIO (Phio Pharmaceuticals Corp.)

Blue Low-Carbon Ammonia Industry: Current Status, Trends, Outlook, and Strategic Recommendations Report 2026

3.7.4 Qatar Fertiliser Company: Company Profile and Core Business 3.7.5 Qatar Fertiliser Company: Latest Corporate Developments 3.8 Ma’aden 3.8.1 Ma’aden: Basic Information, Blue Low-Carbon Ammonia Production Base, Headquarters, Competitors, and Market Position 3.8.2 Ma’aden: Blue Low-Carbon Ammonia Product Specifications, Parameters, and Market Applications 3.8.3 Ma’aden: Blue Low-Carbon Ammonia Sales Volume, Revenue, Pricing, and Gross Margin in the Chinese Market (2021–2026) 3.8.4 Ma’aden: Company Profile and Core Business 3.8.5 Ma’aden: Latest Corporate Developments 3.9 PAO NOVATEK 3.9.1 PAO NOVATEK: Basic Information, Blue Low-Carbon Ammonia Production Base, Headquarters, Competitors, and Market Position 3.9.2 PAO NOVATEK: Blue Low-Carbon Ammonia Product Specifications, Parameters, and Market Applications 3.9.3 PAO NOVATEK: Blue Low-Carbon Ammonia Sales Volume, Revenue, Pricing, and Gross Margin in the Chinese Market (2021–2026) 3.9.4 PAO NOVATEK: Company Profile and Core Business 3.9.5 PAO NOVATEK: Latest Corporate Developments 3.10 ADNOC Group 3.10.1 ADNOC Group: Basic Information, Blue Low-Carbon Ammonia Production Base, Headquarters, Competitors, and Market Position 3.10.2 ADNOC Group: Blue Low-Carbon Ammonia Product Specifications, Parameters, and Market Applications 3.10.3 ADNOC Group: Blue Low-Carbon Ammonia Sales Volume, Revenue, Pricing, and Gross Margin in the Chinese Market (2021–2026) 3.10.4 ADNOC Group: Company Profile and Core Business 3.10.5 ADNOC Group: Latest Corporate Developments 3.11 LSB Industries 3.11.1 LSB Industries: Basic Information, Blue Low-Carbon Ammonia Production Base, Headquarters, Competitors, and Market Position 3.11.2 LSB Industries: Blue Low-Carbon Ammonia Product Specifications, Parameters, and Market Applications 3.11.3 LSB Industries: Blue Low-Carbon Ammonia Sales Volume, Revenue, Pricing, and Gross Margin in the Chinese Market (2021–2026) 3.11.4 LSB Industries: Company Profile and Core Business 3.11.5 LSB Industries: Latest Corporate Developments 3.12 Equinor 3.12.1 Equinor: Basic Information, Blue Low-Carbon Ammonia Production Base, Headquarters, Competitors, and Market Position 3.12.2 Equinor: Blue Low-Carbon Ammonia Product Specifications, Parameters, and Market Applications 3.12.3 Equinor: Blue Low-Carbon Ammonia Sales Volume, Revenue, Pricing, and Gross Margin in the Chinese Market (2021–2026) 3.12.4 Equinor: Company Profile and Core Business

LSB Industries (LXU) Q1 EPS Turnaround Tests Bullish Margin Narratives

May 1, 2026

LSB Industries reported a Q1 2026 turnaround to profitability with US$0.27 EPS and US$19.7 million net income. Despite bullish margin narratives, risks from high debt and forecast declines maintain a balanced market consensus.

Simply Wall Street

2026-04-30

LSB Industries, Inc. Reports Operating Results for Q1 2026

2026-04-30

LSB Industries Reports Strong First-Quarter 2026 Earnings Growth

2026-05-01

LSB Industries (LXU) Q1 EPS Turnaround Tests Bullish Margin Narratives

2026-05-01

LSB Industries, Inc. (NYSE:LXU) Q1 2026 Earnings Call Transcript

2026-05-03

LSB Industries Reports Q1 2026 Earnings Beat